Vor Biopharma (VOR) filed a registration statement Tuesday covering the potential resale of up to 125.7 million common shares of the company from time to time by certain stockholders.
The statement consists of roughly 55.9 million shares held by the selling stockholders and 69.8 million shares issuable upon the exercise of certain outstanding warrants, the company said.
The company will not receive any proceeds from the resale of stock, but will receive proceeds from the exercise of warrants, which will be used to fund clinical and preclinical development of candidate pipeline and for general corporate purposes.
Vor Biopharma shares were down over 4% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.